pharma · Hemophagocytic lymphohistiocytosis (HLH) · Multiple sclerosis
PARItec
Pari Pharma GmbH
Pari Pharma is a pharma organization headquartered in Starnberg, DE. Primary therapeutic focus areas include Hemophagocytic lymphohistiocytosis (HLH), Multiple sclerosis, Acute Myocardial Infarction, Familial Mediterrane
Company details
- Status
- Public
- HQ
- Starnberg, DE
- Employees
- 28
- Programs
- 248
- Drugs
- 362
- Patents
- 0
APHP200072
Phase 3 · small molecule · Patients referred for an isolated or a combined surgical correction of functional moderate to severe tricuspid regurgitation
APHP200072 for Patients referred for an isolated or a combined surgical correction of functional moderate to severe tricuspid regurgitation is a Phase 3 program (small_molecule) at Pari Pharma GmbH with 1 ClinicalTrials.gov record(s).
Internal code APHP200072
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Pari Pharma GmbH
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Patients referred for an isolated or a combined surgical correction of functional moderate to severe tricuspid regurgitation
- Status
- active
- Trials
- 1